Phase 1 Study of QLS1317 for MSI-H/dMMR Advanced Solid Tumors
ClinicalTrials.gov Studies
Summary
A new Phase 1 clinical trial (NCT07552376) has been registered on ClinicalTrials.gov, evaluating the efficacy and safety of the investigational drug QLS1317. The study enrolls patients diagnosed with MSI-H or dMMR advanced solid tumors who have previously failed standard treatment. This is an early-phase oncology study with no regulatory approval or compliance obligations imposed on external parties.
“The goal of this study aims to evaluate the efficacy and safety of QLS1317 in patients with MSI-H/dMMR advanced solid tumors who failed standard treatment.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
A new clinical trial registration for NCT07552376 was published on ClinicalTrials.gov under NIH, documenting a Phase 1 study of the investigational drug QLS1317 in patients with MSI-H or dMMR advanced solid tumors. The trial is listed as Phase 1 with an anticipated registration date of April 27, 2026.
This registry entry does not impose any compliance obligations on manufacturers, sponsors, healthcare providers, or patients. It is an informational record of an ongoing clinical investigation. Sponsors or clinical investigators associated with similar oncology trials in solid tumors may reference this entry for competitive landscape awareness, but no regulatory action is triggered by this publication.
Archived snapshot
Apr 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
This Study Aims to Evaluate the Efficacy and Safety of QLS1317 in Patients With MSI-H/dMMR Advanced Solid Tumors.
Phase 1 NCT07552376 Kind: PHASE1 Apr 27, 2026
Abstract
The goal of this study aims to evaluate the efficacy and safety of QLS1317 in patients with MSI-H/dMMR advanced solid tumors who failed standard treatment.
Conditions: MSI-H or dMMR Advanced Solid Tumors
Interventions: QLS1317
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.